LBPH Stock Recent News

NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Longboard Pharmaceuticals, Inc . (Nasdaq : LBPH ), relating to a tender offer from H. Lundbeck A/S. Under the terms of the agreement, H. Lundbeck offers to acquire outstanding shares of Longboard common stock for $60.00 per share.

LBPH stock soars 52% on announcing that it is set to be acquired by Lundbeck for a total consideration of $2.6 billion to bolster the latter's neuro pipeline.

NEW YORK , Oct. 14, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) and its board of directors concerning the proposed acquisition of the company by H. Lundbeck A/S.

Longboard shareholders will be offered $60 per share in cash.

VALBY, Denmark & LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--H. Lundbeck A/S (Lundbeck) and Longboard Pharmaceuticals, Inc (NASDAQ: LBPH) (Longboard) today announced an agreement for Lundbeck to acquire Longboard. Under the terms of the agreement, Lundbeck will commence a tender offer for all outstanding shares of Longboard common stock, whereby Longboard shareholders will be offered a payment of USD 60.00 per share in cash. The transaction is valued at approximately USD 2.6 billion equity value and USD.

Q2 2024 Longboard Pharmaceuticals Inc Earnings Call and Discussi {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"GuruFocus.com","item":"https://www.gurufocus.com"},{"@type":"ListItem","position":2,"name":"Latest News","item":"https://www.gurufocus.com/latest-news"},{"@type":"ListItem","position":3,"name":"U.S.","item":"https://www.gurufocus.com/latest-news/usa"},{"@type":"ListItem","position":4,"name":"Biotechnology","item":"https://www.gurufocus.com/latest-news/usa/biotechnology"},{"@type":"ListItem","position":5,"name":"NAS:LBPH","item":"https://www.gurufocus.

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has initiated its global Phase 3 DEEp SEA Study evaluating its investigational drug bexicaserin for the treatment of seizures associated with Dravet syndrome in participants two years of age and older. “We are thrilled to announce the initiation of our global Phase 3.

The FDA grants orphan drug and rare pediatric disease designations to LBPH's lead pipeline drug for the treatment of Dravet Syndrome.

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will host an Investor & Analyst Event which will feature updates for the planned global Phase 3 Program evaluating bexicaserin (LP352), a first-in-class 5-HT2C receptor superagonist in development for the treatment of seizures associated with Developmental and Epi.